Skip to main content

Urgo patient

Menu
URGO MEDICAL Healing People

THE ONLY ANTI-BIOFILM SILVER DRESSING THAT SUPPORTS CONTINUOUS INTEGRAL DEBRIDEMENT OF SLOUGH.

Supports continuous integral debridement of slough

Destroys the biofilm and prevents its reformation

Demonstrate activity against signs of local infection

50% greater debridement of slough versus Hydrofiber technology in a randomised controlled trial.

Real-world efficacy documented in an observational study of more than 2,270 patients.

UrgoClean Ag Product Image

The only anti-biofilm silver dressing that supports continuous integral debridement of slough.

Supports continuous
integral debridement
of slough
Destroys the
biofilm and prevents
its reformation
Demonstrates
activity against signs
of local infection

What is UrgoClean Ag Dressing?

UrgoClean Ag is an anti-biofilm silver dressing that supports the continuous debridement of slough.1,2 It is powered by 2 key technologies: Technology Lipido-Colloid-Ag (TLC-Ag) technology and Magnet Fibres technology (polyabsorbent fibres).

UrgoClean Ag Dressing

TLC-Ag Technology TLC-Ag Technology + Magnet Fibres Technology Magnet Fibres Technology

The TLC-Ag technology, combined with Magnet Fibres, provides continuous debridement to keep wounds clean, as well as anti-biofilm and antimicrobial efficacy for effective management of infection and infection risk.

UrgoClean Ag is:

  1. Effective: Anti-Biofilm dressing that is proven to promotes healing by maximises debridement effect through the continuous removal of slough, wound debris and mitigates reformation of microbial colonies.
  2. Easy to Access: Accessible to all caregivers (both tertiary hospital to primary care settings in the community) in order to harness the benefits of debridement throughout the continuum of care.
  3. Easy to use & Comfortable: Easy to use and can be easily incorporated into existing practices. Well-tolerated by patients and helps improve Quality of Life for patients.

Continuous Debridement of Slough

Helps to actively sustain the outcomes of cleansing and debridement by supporting continuous debridement. +50% more superior desloughing than other dressings1 for ongoing removal of slough, thanks to the Magnet Fibres Technology.

Antimicrobial Efficacy

UrgoClean Ag is also powered by TLC-Ag technology, similar to UrgoTul Ag. It offers fast and broad spectrum antimicrobial efficacy, including on strains resistant to antibiotics. Proven to have superior clinical efficacy to reduce signs of local infection and promote healing in both chronic and acute wounds.3,7

Anti-Biofilm Efficacy

Biofilms limit the action of silver dressings8. While biofilm is removed during debridement, it is found that biofilm can reform at quickly at 24 hours after debridement,9 UrgoClean Ag destroys and removes biofilm within 24h & prevent its reformation for up to 7 days.10

When to Use UrgoClean Ag

Consider using UrgoClean Ag (pad format) as your dressing choice to support debridement as part of the Continuous Integral Debridement framework.

Wounds at risk of or presenting with signs of local infection.

Chronic wounds characterised by sloughy tissue or biofilm, including:

  • Leg ulcers
  • Diabetic foot ulcers
  • Pressure ulcers

Acute wounds requiring effective debridement and bacterial load management, such as:

  • Burns
  • Abrasions
  • Traumatic wounds
  • Post-operative wounds

How to use UrgoClean Ag dressing

1

Prepare the wound

Therapeutically cleanse the wound with an appropriate wound cleanser. If antiseptics were used previously, ensure the wound is carefully rinsed with saline before applying the dressing.

While UrgoClean Ag continuously debrides the wound, it does not replace the need for associated sharp or mechanical debridement when clinically indicated. Be aware that the wound may initially appear larger as slough is gradually removed

Prepare the wound with UrgoClean Ag

2

Apply the UrgoClean Ag dressing

Carefully remove the protective tabs.

Place the micro-adherent side (brown side) of the UrgoClean Ag dressing directly onto the wound surface, ensuring full contact with its edges.

If needed, the dressing can be cut with sterile scissors to perfectly fit the wound size and shape.

Due to it’s non-adherent properties, allow a 1-2cm overlap onto the surrounding skin to minimize dressing movement.

Cover the UrgoClean Ag with an appropriate secondary dressing that is appropriate for the wound’s location and level of exudate.

Secure the entire dressing assembly firmly in place with a suitable bandage or medical tape.

Apply a compression bandage, such as UrgoK2, as prescribed by the clinician for conditions like venous leg ulcers.

Apply the UrgoClean Ag dressing

3

Optimise dressing changes

During the continuous debridement phase, it is recommended to change the UrgoClean Ag every 1 to 2 days to ensure continuous action.

Slightly increased levels of exudate are normal during the initial phase of wound management.

Subsequently, the dressing can be changed as frequently as required. UrgoClean Ag dressing can be left in place for up to a maximum of 7 days, depending on the wound’s clinical condition and exudate volume.

The total treatment duration with UrgoClean Ag should not exceed 1 month.

Changing the UrgoClean Ag dressing

FEATURES

FEATURES BENEFITS

Supports continuous debridement of slough1,2

✔️ Fibrin, microorganisms, and wound residue attach to the Magnet Fibres of the dressing to continuously clean the wound bed2

✔️ Anti-biofilm dressing assists in maintaining a clean wound bed, optimizing silver efficacy in the wound2,8,10

Destroys the biofilm and prevents its reformation10

✔️ 99.99% biofilm reduction within 24 hours8

✔️ Superior and more rapid anti-biofilm efficacy compared to Aquacel ag+ Extra and Cutimed Sorbact8,11

✔️ Prevents biofilm reformation for up to 7 days10

Effectively fights against signs of local infection2,3,7,10

✔️ Fast and broad spectrum antimicrobial efficacy, including strains resistant to antibiotics6,10

✔️ Superior clinical efficacy in promoting healing for both chronic and acute wounds2

Comfort and ease of use2

✔️ One piece removal thanks to strong acrylic core2

✔️ Ensures pain-free care and atraumatic removal2

Get in Touch with Our Representative for More Information About the UrgoClean Ag

Contact us

References

  1. Meaume S. et al. Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT). J Wound Care, March 2014, Vol 23, No.3; 105-116
  2. Dalac S., Sigal L., Addala A., et al Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial. J Wound Care, Vol 25, No 9, September 2016
  3. Dissemond J. et al, Use of a TLC-Ag dressing on 2270 patients with wounds at risk or with signs of local infection: an observational study, J Wound Care, volume 29, number 3, march 2020
  4. In vitro study report RE/UR/2025-201/CHC
  5. In vitro data. Nexidia reports 2021-11F and 2021-11D v2.
  6. Internal data – Laboratoires Urgo
  7. Lazareth I, et al. The role of a silver releasing lipido-colloid contact layer in venous leg ulcers presenting inflammatory signs suggesting heavy bacterial colonization: Results of a randomized controlled study. Wounds. 2008;20(6):158–66
  8. Percival SL. Restoring balance: biofilms and wound dressings. J Wound Care 2018; 27: 102-113..
  9. Schultz, G. et al (2017), Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Rep and Reg, 25: 744-757
  10. Desroche N, Dropet C, Janod P, et al. Antibacterial properties and reduction of MRSA biofilm with a dressing combining polyabsorbent fibres and a silver matrix. J Wound Care 2016; 25: 577-584.
  11. N. Desroche et al. Evaluation of in-vitro anti-biofilm activities of two dressings with poly-absorbent dressing and a DACC-coated dressing. Poster EWMA 2017

INDICATIONS

UrgoClean Ag Pad is indicated for the local management of cutaneous wounds, thanks to the main action of wound protection and healing in moist environment.
UrgoClean Ag Pad is particularly intended for use on wounds at risk or with clinical signs of local infection, thanks to the antimicrobial secondary action of silver ions, with the aim of reducing the bacterial load locally and the risk of infection.

Cutaneous wounds include:
• Chronic wounds: leg ulcers, pressure ulcers, diabetic foot ulcers.
• Acute wounds: partial thickness burns, traumatic wounds, post-surgical wounds.

For surgical wounds, application of UrgoClean Ag Pad should be restricted for specific surgical situation regarding high-risk patients undergoing high-risk procedures and only for a limited extent and should not be used as a surgical sponge for heavily bleeding wounds. For a highly exuding wound (that is, a wound with a high amount of fluid), UrgoClean Ag Pad can be covered with an additional absorbent dressing. UrgoClean Ag Pad must be secured with a dressing securement system (for example, medical tape, flat, tubular mesh, or adhesive dressing).

Get in Touch with Our Representative for More Information About the UrgoClean Ag

Contact us

References

  1. Meaume S. et al. Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT). J Wound Care, March 2014, Vol 23, No.3; 105-116
  2. Dalac S., Sigal L., Addala A., et al Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial. J Wound Care, Vol 25, No 9, September 2016
  3. Dissemond J. et al, Use of a TLC-Ag dressing on 2270 patients with wounds at risk or with signs of local infection: an observational study, J Wound Care, volume 29, number 3, march 2020
  4. In vitro study report RE/UR/2025-201/CHC
  5. In vitro data. Nexidia reports 2021-11F and 2021-11D v2.
  6. Internal data – Laboratoires Urgo
  7. Lazareth I, et al. The role of a silver releasing lipido-colloid contact layer in venous leg ulcers presenting inflammatory signs suggesting heavy bacterial colonization: Results of a randomized controlled study. Wounds. 2008;20(6):158–66
  8. Percival SL. Restoring balance: biofilms and wound dressings. J Wound Care 2018; 27: 102-113..
  9. Schultz, G. et al (2017), Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Rep and Reg, 25: 744-757
  10. Desroche N, Dropet C, Janod P, et al. Antibacterial properties and reduction of MRSA biofilm with a dressing combining polyabsorbent fibres and a silver matrix. J Wound Care 2016; 25: 577-584.
  11. N. Desroche et al. Evaluation of in-vitro anti-biofilm activities of two dressings with poly-absorbent dressing and a DACC-coated dressing. Poster EWMA 2017

CONTRAINDICATIONS

  • Mucous membrane wounds..
  • Haemorrhagic wounds: UrgoClean Ag Pad can be used to help stop minor bleeding but should not be used as a surgical sponge.
  • Known hypersensitivity of the patient to silver, or to one of the components of the TLC or TLC-Ag dressings, or to carboxymethylcellulose (CMC).
  • Do not use UrgoClean Ag Pad on patients who are due to undergo magnetic resonance imaging (MRI) examination.

Get in Touch with Our Representative for More Information About the UrgoClean Ag

Contact us

References

  1. Meaume S. et al. Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT). J Wound Care, March 2014, Vol 23, No.3; 105-116
  2. Dalac S., Sigal L., Addala A., et al Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial. J Wound Care, Vol 25, No 9, September 2016
  3. Dissemond J. et al, Use of a TLC-Ag dressing on 2270 patients with wounds at risk or with signs of local infection: an observational study, J Wound Care, volume 29, number 3, march 2020
  4. In vitro study report RE/UR/2025-201/CHC
  5. In vitro data. Nexidia reports 2021-11F and 2021-11D v2.
  6. Internal data – Laboratoires Urgo
  7. Lazareth I, et al. The role of a silver releasing lipido-colloid contact layer in venous leg ulcers presenting inflammatory signs suggesting heavy bacterial colonization: Results of a randomized controlled study. Wounds. 2008;20(6):158–66
  8. Percival SL. Restoring balance: biofilms and wound dressings. J Wound Care 2018; 27: 102-113..
  9. Schultz, G. et al (2017), Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Rep and Reg, 25: 744-757
  10. Desroche N, Dropet C, Janod P, et al. Antibacterial properties and reduction of MRSA biofilm with a dressing combining polyabsorbent fibres and a silver matrix. J Wound Care 2016; 25: 577-584.
  11. N. Desroche et al. Evaluation of in-vitro anti-biofilm activities of two dressings with poly-absorbent dressing and a DACC-coated dressing. Poster EWMA 2017

PRECAUTIONS

✔️ Treatment with UrgoClean Ag should be carried out under medical supervision.

✔️ Use of this dressing does not negate the need for appropriate systemic anti-bacterial treatment of infected wounds in line with local policy.

✔️ The soft-adherent Silver Healing Matrix (TLC-Ag) of UrgoClean Ag adheres to latex surgical gloves. It is therefore recommended that the dressing be handled carefully, avoiding any contact with the soft-adherent side or using sterile pliers.

✔️ Concomitant use with other local treatments is not recommended.

✔️ Avoid contact with electrodes or conductive gels during electronic measurements, e.g. EEG and ECG.

✔️ Clinicians / Healthcare Professionals should be aware that there are very limited data on prolonged and repeated use of silver containing dressings, particularly in children and neonates.

✔️ In the absence of any specific clinical data, use in pregnant or breast-feeding women, is not recommended.

✔️ Do not use in a hyperbaric chamber.

✔️ Single-use, individual packaging. Re-using a single use dressing may lead to risks of infection. Check that the sterile protector is intact before use.

✔️ Do not re-sterilise.

✔️ For elimination, discard according to current protocol. Discard any unused parts of the dressing.

For a complete list of precautions, contraindications, and indications, please contact your local sales representative to obtain the Instructions for Use (IFU).

Get in Touch with Our Representative for More Information About the UrgoClean Ag

Contact us

References

  1. Meaume S. et al. Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT). J Wound Care, March 2014, Vol 23, No.3; 105-116
  2. Dalac S., Sigal L., Addala A., et al Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial. J Wound Care, Vol 25, No 9, September 2016
  3. Dissemond J. et al, Use of a TLC-Ag dressing on 2270 patients with wounds at risk or with signs of local infection: an observational study, J Wound Care, volume 29, number 3, march 2020
  4. In vitro study report RE/UR/2025-201/CHC
  5. In vitro data. Nexidia reports 2021-11F and 2021-11D v2.
  6. Internal data – Laboratoires Urgo
  7. Lazareth I, et al. The role of a silver releasing lipido-colloid contact layer in venous leg ulcers presenting inflammatory signs suggesting heavy bacterial colonization: Results of a randomized controlled study. Wounds. 2008;20(6):158–66
  8. Percival SL. Restoring balance: biofilms and wound dressings. J Wound Care 2018; 27: 102-113..
  9. Schultz, G. et al (2017), Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Rep and Reg, 25: 744-757
  10. Desroche N, Dropet C, Janod P, et al. Antibacterial properties and reduction of MRSA biofilm with a dressing combining polyabsorbent fibres and a silver matrix. J Wound Care 2016; 25: 577-584.
  11. N. Desroche et al. Evaluation of in-vitro anti-biofilm activities of two dressings with poly-absorbent dressing and a DACC-coated dressing. Poster EWMA 2017

CUTTING GUIDE

Get in Touch with Our Representative for More Information About the UrgoClean Ag

Contact us

References

  1. Meaume S. et al. Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT). J Wound Care, March 2014, Vol 23, No.3; 105-116
  2. Dalac S., Sigal L., Addala A., et al Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial. J Wound Care, Vol 25, No 9, September 2016
  3. Dissemond J. et al, Use of a TLC-Ag dressing on 2270 patients with wounds at risk or with signs of local infection: an observational study, J Wound Care, volume 29, number 3, march 2020
  4. In vitro study report RE/UR/2025-201/CHC
  5. In vitro data. Nexidia reports 2021-11F and 2021-11D v2.
  6. Internal data – Laboratoires Urgo
  7. Lazareth I, et al. The role of a silver releasing lipido-colloid contact layer in venous leg ulcers presenting inflammatory signs suggesting heavy bacterial colonization: Results of a randomized controlled study. Wounds. 2008;20(6):158–66
  8. Percival SL. Restoring balance: biofilms and wound dressings. J Wound Care 2018; 27: 102-113..
  9. Schultz, G. et al (2017), Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Rep and Reg, 25: 744-757
  10. Desroche N, Dropet C, Janod P, et al. Antibacterial properties and reduction of MRSA biofilm with a dressing combining polyabsorbent fibres and a silver matrix. J Wound Care 2016; 25: 577-584.
  11. N. Desroche et al. Evaluation of in-vitro anti-biofilm activities of two dressings with poly-absorbent dressing and a DACC-coated dressing. Poster EWMA 2017

DIRECTIONS FOR USE

Get in Touch with Our Representative for More Information About the UrgoClean Ag

Contact us

References

  1. Meaume S. et al. Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT). J Wound Care, March 2014, Vol 23, No.3; 105-116
  2. Dalac S., Sigal L., Addala A., et al Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial. J Wound Care, Vol 25, No 9, September 2016
  3. Dissemond J. et al, Use of a TLC-Ag dressing on 2270 patients with wounds at risk or with signs of local infection: an observational study, J Wound Care, volume 29, number 3, march 2020
  4. In vitro study report RE/UR/2025-201/CHC
  5. In vitro data. Nexidia reports 2021-11F and 2021-11D v2.
  6. Internal data – Laboratoires Urgo
  7. Lazareth I, et al. The role of a silver releasing lipido-colloid contact layer in venous leg ulcers presenting inflammatory signs suggesting heavy bacterial colonization: Results of a randomized controlled study. Wounds. 2008;20(6):158–66
  8. Percival SL. Restoring balance: biofilms and wound dressings. J Wound Care 2018; 27: 102-113..
  9. Schultz, G. et al (2017), Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Rep and Reg, 25: 744-757
  10. Desroche N, Dropet C, Janod P, et al. Antibacterial properties and reduction of MRSA biofilm with a dressing combining polyabsorbent fibres and a silver matrix. J Wound Care 2016; 25: 577-584.
  11. N. Desroche et al. Evaluation of in-vitro anti-biofilm activities of two dressings with poly-absorbent dressing and a DACC-coated dressing. Poster EWMA 2017

PRODUCT OPTIONS

Product Size Units/Box
6x6cm 10
10x10cm 10
15x20cm 5

Get in Touch with Our Representative for More Information About the UrgoClean Ag

Contact us

References

  1. Meaume S. et al. Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT). J Wound Care, March 2014, Vol 23, No.3; 105-116
  2. Dalac S., Sigal L., Addala A., et al Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial. J Wound Care, Vol 25, No 9, September 2016
  3. Dissemond J. et al, Use of a TLC-Ag dressing on 2270 patients with wounds at risk or with signs of local infection: an observational study, J Wound Care, volume 29, number 3, march 2020
  4. In vitro study report RE/UR/2025-201/CHC
  5. In vitro data. Nexidia reports 2021-11F and 2021-11D v2.
  6. Internal data – Laboratoires Urgo
  7. Lazareth I, et al. The role of a silver releasing lipido-colloid contact layer in venous leg ulcers presenting inflammatory signs suggesting heavy bacterial colonization: Results of a randomized controlled study. Wounds. 2008;20(6):158–66
  8. Percival SL. Restoring balance: biofilms and wound dressings. J Wound Care 2018; 27: 102-113..
  9. Schultz, G. et al (2017), Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Rep and Reg, 25: 744-757
  10. Desroche N, Dropet C, Janod P, et al. Antibacterial properties and reduction of MRSA biofilm with a dressing combining polyabsorbent fibres and a silver matrix. J Wound Care 2016; 25: 577-584.
  11. N. Desroche et al. Evaluation of in-vitro anti-biofilm activities of two dressings with poly-absorbent dressing and a DACC-coated dressing. Poster EWMA 2017

CLINICAL EVIDENCE

 

Get in Touch with Our Representative for More Information About the UrgoClean Ag

Contact us

References

  1. Meaume S. et al. Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT). J Wound Care, March 2014, Vol 23, No.3; 105-116
  2. Dalac S., Sigal L., Addala A., et al Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial. J Wound Care, Vol 25, No 9, September 2016
  3. Dissemond J. et al, Use of a TLC-Ag dressing on 2270 patients with wounds at risk or with signs of local infection: an observational study, J Wound Care, volume 29, number 3, march 2020
  4. In vitro study report RE/UR/2025-201/CHC
  5. In vitro data. Nexidia reports 2021-11F and 2021-11D v2.
  6. Internal data – Laboratoires Urgo
  7. Lazareth I, et al. The role of a silver releasing lipido-colloid contact layer in venous leg ulcers presenting inflammatory signs suggesting heavy bacterial colonization: Results of a randomized controlled study. Wounds. 2008;20(6):158–66
  8. Percival SL. Restoring balance: biofilms and wound dressings. J Wound Care 2018; 27: 102-113..
  9. Schultz, G. et al (2017), Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Rep and Reg, 25: 744-757
  10. Desroche N, Dropet C, Janod P, et al. Antibacterial properties and reduction of MRSA biofilm with a dressing combining polyabsorbent fibres and a silver matrix. J Wound Care 2016; 25: 577-584.
  11. N. Desroche et al. Evaluation of in-vitro anti-biofilm activities of two dressings with poly-absorbent dressing and a DACC-coated dressing. Poster EWMA 2017

OTHER PRODUCTS

UrgoTul Ag
UrgoTul Ag
 View

You are being redirected our of URGO Medical APAC website. The content on the subsequent website is intended for and only applicable to the market’s home audience.

Do you wish to proceed? 

No